SG&A Expense Trends: Viatris Inc. vs ADMA Biologics, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and ADMA Biologics, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced ADMA Biologics, Inc. in SG&A spending, reflecting its larger scale and broader market reach. In 2023, Viatris's SG&A expenses were approximately 79 times higher than ADMA's, highlighting its expansive operational footprint. Notably, ADMA Biologics, Inc. demonstrated a significant upward trend, with a nearly 12-fold increase in SG&A expenses over the decade, indicating its aggressive growth strategy. This financial trajectory underscores the contrasting business models: Viatris's established market dominance versus ADMA's rapid expansion. As the industry continues to innovate, these trends offer valuable insights into the strategic priorities of these pharmaceutical giants.